Annual report pursuant to Section 13 and 15(d)

Segment Reporting - Summary of Net Revenue, Cost of Sales, Operating Profit, Depreciation and Amortization, Interest Expense, Income Tax Benefit (Expense), Other Comprehensive Income, and Assets by Segment (Detail)

v3.8.0.1
Segment Reporting - Summary of Net Revenue, Cost of Sales, Operating Profit, Depreciation and Amortization, Interest Expense, Income Tax Benefit (Expense), Other Comprehensive Income, and Assets by Segment (Detail) - USD ($)
 12 Months Ended
Nov. 30, 2017
Nov. 30, 2016
Segment Reporting Information [Line Items]    
Total net revenue $ 25,384,279 $ 23,128,047
Total cost of sales 6,724,391 5,774,800
Total operating profit 5,006,226 433,594
Total depreciation and amortization 229,995 286,650
Total interest expense 1,302,650 947,340
Total income tax (expense) benefit (1,308,603) 1,159,412
Total other comprehensive income (loss) 6,457 (135,524)
Total assets 23,909,997 19,538,468
Umbilical Cord Blood and Cord Tissue Stem Cell Service [Member]    
Segment Reporting Information [Line Items]    
Total net revenue 24,942,089 22,777,919
Total cost of sales 6,257,628 5,446,126
Total operating profit 5,067,228 2,447,160
Total depreciation and amortization 193,741 240,916
Total interest expense 1,302,650 925,075
Total income tax (expense) benefit (1,308,603) 1,141,823
Total other comprehensive income (loss) 6,457 (135,524)
Total assets 23,360,714 18,960,261
PrepaCyte CB [Member]    
Segment Reporting Information [Line Items]    
Total net revenue 442,190 350,128
Total cost of sales 466,763 328,674
Total operating profit (61,002) (2,013,566)
Total depreciation and amortization 36,254 45,734
Total interest expense   22,265
Total income tax (expense) benefit   17,589
Total assets $ 549,283 $ 578,207